Caraco Pharmaceutical Laboratories Ltd

Caraco Pharmaceutical Laboratories — Investor Presentation (March 2007)

24 slides from Caraco Pharmaceutical Laboratories's investor presentation, Mar 6, 2007

  1. Slide 1: Caraco Pharmaceutical Laboratories, Ltd.

    Caraco Pharmaceutical Laboratories, Ltd.

  2. Slide 2: Safe Harbor

    Safe Harbor: This presentation contains forward- looking statements made pursuant to the safe- harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual

  3. Slide 3: Generic Pharmaceutical Industry Overview

    Generic Pharmaceutical Industry Overview The Generic Pharmaceutical Industry Primarily Consists of Generic Versions of Brand Pharmaceuticals that have Lost Their Patent Exclusivity or are Products that do not Infringe the Innovator’s Patent U.S. Brand Pharmaceutical Sales for 2005 were $229.5 billio

  4. Slide 4: Company Overview

    Caraco Pharmaceutical Laboratories, Ltd. Company Overview Established in 1984, Based in Detroit, MI Caraco Develops, Manufactures, Markets and Distributes Generic and Private-label Pharmaceuticals In 1997, Sun Pharmaceutical Industries Inc. Invested $7.5 Million in Caraco Through a Stock Purchase Ag

  5. Slide 5: Sun Pharmaceutical Industries, Ltd.

    Sun Pharmaceutical Industries, Ltd. Established in 1983, Sun Focuses on Specialty Pharmaceuticals and Active Pharmaceutical Ingredients (API’s) Fifth Largest Pharmaceutical Company in India Together, the Technology Transfer and Marketing Agreements Currently Represent 61 Products Awaiting Approval a

  6. Slide 6: What sets us apart?

    Caraco Pharmaceutical Laboratories, Ltd. What sets us apart? Size of our Product Portfolio vs. the Size of Company Experienced Management Team Vertically Integrated via Sun API’s Disciplined Management Ability to Service our Customers’ Immediate Needs

  7. Slide 7: Overview: What sets us apart?

    Caraco Overview What sets us apart? Diverse Paths of Development Building to fit the Current Environment Improved Customer Mix Removal of Barriers, Execution

  8. Slide 8: Product Market Share Trends

    Caraco Pharmaceutical Laboratories, Ltd. Product Market Share Trends Caraco is Currently Marketing 27 Generic Pharmaceuticals and One Brand Product Caraco Launched One Product in the Third Quarter of Fiscal 2007; YTD Caraco has Launched Four Products 14 of the 27 Products are in the Top Three of Gen

  9. Slide 9: Product Market Share Trends

    Caraco Pharmaceutical Laboratories, LTD Product Market Share Trends ZONISAMIDE Zonegran ® BACLOFEN Lioresal ® TIZANIDINE Zanaflex ® DIGOXIN Lanoxin ® TRAMADOL W/ APAP Ultracet ® CLONAZEPAM Klonopin ® TRAMADOL Ultram ® PAROMOMYCIN** Humatin ® CHOLINE MAG Trilisate ® GLIPIZIDE Glucotrol ® TICLOPIDINE

  10. Slide 10: Financial Overview

    Caraco Pharmaceutical Laboratories, Ltd. Financial Overview Surpassed Record Annual Sales and Net Income Through Nine Months of Fiscal 2007 ($84 Million); Net Sales Growth of 45% Over Corresponding Period of Fiscal 2006 Year-to-Date Gross Profit Margin of Approximately 49%, which is Above the Generi

  11. Slide 11: Annual Historical Results

    Caraco Pharmaceutical Laboratories, Ltd. Annual Historical Results (in US $ millions) *Change in fiscal year

  12. Slide 12: Net Sales for Fiscal 2007 (YTD)

    Caraco Pharmaceutical Laboratories, Ltd. Net Sales for Fiscal 2007 (YTD) (in US $ millions) * Change in fiscal year

  13. Slide 13: Third Quarter Fiscal 2007 Financial Overview

    Third Quarter Fiscal 2007 Financial Overview Third Quarter Net Sales Growth of 51% Gross Profit Margin of 48% Successive Quarterly Growth of 11% over the Second Quarter of 2007

  14. Slide 14: Quarterly Analysis

    Caraco Pharmaceutical Laboratories, Ltd. Quarterly Analysis (in US $ millions)

  15. Slide 15: Net Sales by Trade Class

    Caraco Pharmaceutical Laboratories, Ltd. Net Sales by Trade Class

  16. Slide 16: Net Sales by Trade Class

    Caraco Pharmaceutical Laboratories, Ltd. Net Sales by Trade Class Growth Percentages Chain : 244.7% Dist : 21.5% Whole : 122.9% Mg Care : 50.5% Govt : 15.4%

  17. Slide 17: Third Quarter Fiscal 2007 Highlights

    Third Quarter Fiscal 2007 Highlights Signed Two Definitive Agreements Recognized by One of the “Big Three Wholesalers” in US as Best Trade Representative for Companies Under $100 Million in Sales with that Wholesaler Launched Phenytoin ER Filed Two ANDAs with FDA (7 YTD) Bringing Total Products Awai

  18. Slide 18: Product Development Quarterly Filings (ANDAs)

    Caraco Pharmaceutical Laboratories, Ltd. Product Development Quarterly Filings (ANDAS) *Includes two tentative FDA approvals

  19. Slide 19: Capacity

    Capacity Current Owned Facilities are 114,000 sq ft and Lease Another 67,000 sq ft for Total Footprint of Approximately 180,000 sq ft Need to Build 100,000 - 125,000 sq ft Facility or Move to 250,000 sq. ft cGMP Facility for Complete Company Move Can Expand up to 450,000 sq ft at Current Sites Fisca

  20. Slide 20: Product Litigation

    Product Litigation Lexapro – Teva/IVAX Lost First Case, Teva Appealed Decision on November 6, 2006; Possible Upside if Caraco Prevails. Forest was Denied Motion to Transfer its Action Against Caraco to the United States District Court for the District of Delaware; the Litigation will Proceed in East

  21. Slide 21: Drivers Fiscal 2008

    Drivers Fiscal 2008 Approvals – Phenytoin ER Pending Approvals Increase / Maintain Share Increase and Close Alternate Development Projects

  22. Slide 22: Drivers Fiscal 2008

    Drivers Fiscal 2008 Expand Current Development Streams and Pursue New Opportunities Improve Packaging Continue Staff Improvements and Succession Planning

  23. Slide 23: Summary

    Caraco Pharmaceutical Laboratories, Ltd. Summary Well Positioned to Execute Plan We are Built to Fit the Current Competitive Environment Vertical Integration with Sun Allows us to Enjoy Longer Lifecycles and Value on Products that We Market Large Basket of Products Awaiting Approval At FDA

  24. Slide 24: Thank You

    CARACO Thank You

Caraco Pharmaceutical Laboratories — Investor Presentation (March 2007) on 6ix